Journal of International Oncology››2022,Vol. 49››Issue (5): 316-318.doi:10.3760/cma.j.cn371439-20210604-00059
Previous ArticlesNext Articles
Received:2021-06-04Revised:2021-11-03Online:2022-05-08Published:2022-05-31
"
"
"
"
"
"
| [1] | Izuishi K, Mori H. Recent strategies for treating stage Ⅳ gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiotherapy[J]. J Gastrointestin Liver Dis, 2016, 25(1): 87-94. DOI: 10.15403/jgld.2014.1121.251.rv2. doi:10.15403/jgld.2014.1121.251.rv2 |
| [2] | Wang T, Wang N, Ren H, et al. Long-term results of conversion therapy for initially unresectable gastric cancer: analysis of 122 patients at the national cancer center in china[J]. J Cancer, 2019, 10(24): 5975-5985. DOI: 10.7150/jca.35527. doi:10.7150/jca.35527 |
| [3] | Yamaguchi K, Yoshida K, Tanahashi T, et al. The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy[J]. Gastric Cancer, 2018, 21(2): 315-323. DOI: 10.1007/s10120-017-0738-1. doi:10.1007/s10120-017-0738-1pmid:28616743 |
| [4] | Sato Y, Sagawa T, Ohnuma H, et al. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer[J]. Cancer Chemother Pharmacol, 2019, 83(1): 161-167. DOI: 10.1007/s00280-018-3719-0. doi:10.1007/s00280-018-3719-0 |
| [5] | Ramos MFKP, Pereira MA, Charruf AZ, et al. Conversion therapy for gastric cancer: expanding the treatment possibilities[J]. Arq Bras Cir Dig, 2019, 32(2): e1435. DOI: 10.1590/0102-672020190001e1435. doi:10.1590/0102-672020190001e1435 |
| [6] | Gong Y, Wang P, Zhu Z, et al. Benefits of surgery after neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal metastasis: a meta-analysis[J]. J Surg Res, 2020, 245: 234-243. DOI: 10.1016/j.jss.2019.07.044. doi:10.1016/j.jss.2019.07.044 |
| [7] | Cho H, Nakamura J, Asaumi Y, et al. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature[J]. Ann Surg Oncol, 2015, 22(3): 787-792. DOI: 10.1245/s10434-014-4084-9. doi:10.1245/s10434-014-4084-9 |
| [8] | Sugawara N, Ota K, Terazawa T, et al. Endoscopic evaluation of neoadjuvant chemotherapeutic efficacy in gastric cancer before gastrectomy might be as useful as histological assessment after gastrectomy[J]. Digestion, 2020, 101(4): 466-472. DOI: 10.1159/000500907. doi:10.1159/000500907pmid:31256160 |
| [9] | Kurokawa Y, Shibata T, Sasako M, et al. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A)[J]. Gastric Cancer, 2014, 17(3): 514-521. DOI: 10.1007/s10120-013-0294-2. doi:10.1007/s10120-013-0294-2 |
| [10] | Derieux S, Svrcek M, Manela S, et al. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard’s Tumor Regression Grade (TRG) in gastric adenocarcinoma[J]. Dig Liver Dis, 2020, 52(1): 107-114. DOI: 10.1016/j.dld.2019.07.010. doi:10.1016/j.dld.2019.07.010 |
| [11] | Qin R, Yang Y, Chen H, et al. Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling[J]. Clin Proteomics, 2020, 17: 4. DOI: 10.1186/s12014-020-9267-8. doi:10.1186/s12014-020-9267-8 |
| [12] | Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors[J]. Int J Cancer, 2014, 134(3): 622-628. DOI: 10.1002/ijc.28373. doi:10.1002/ijc.28373pmid:23832847 |
| [13] | Badgwell B, Ikoma N, Murphy MB, et al. A phase Ⅱ trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology[J]. Ann Surg Oncol, 2021, 28(1): 258-264. DOI: 10.1245/s10434-020-08739-5. doi:10.1245/s10434-020-08739-5 |
| [14] | Badgwell B, Blum M, Das P, et al. Phase Ⅱ trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma[J]. Ann Surg Oncol, 2017, 24(11): 3338-3344. DOI: 10.1245/s10434-017-6047-4. doi:10.1245/s10434-017-6047-4pmid:28799004 |
| [15] | Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-a meta-analysis of randomised and high-quality non-randomised stu-dies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer[J]. Eur J Cancer, 2017, 79: 1-14. DOI: 10.1016/j.ejca.2017.03.030. doi:S0959-8049(17)30868-7pmid:28456089 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
